董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 余国良 | 男 | Chairman of the Board and Chief Executive Officer | 61 | 未披露 | 868.30 | 2024-05-06 |
| Wendy Hayes | 女 | Director | 54 | 未披露 | 1.39 | 2024-05-06 |
| Chen, Hong Jung | 男 | Director | 64 | 未披露 | 639.02 | 2024-05-06 |
| Sanjeev Redkar | 男 | President and Director | 55 | 未披露 | 722.08 | 2024-05-06 |
| Kenneth C. Carter | 男 | Director | 64 | 未披露 | 1.39 | 2024-05-06 |
| Glenn S. Vraniak | 男 | Director | 61 | 未披露 | 1.39 | 2024-05-06 |
| Bob Lin | 男 | Director | -- | 未披露 | 未持股 | 2024-05-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 余国良 | 男 | Chairman of the Board and Chief Executive Officer | 61 | 未披露 | 868.30 | 2024-05-06 |
| 马修 普朗克特 | 男 | Chief Financial Officer | 52 | 未披露 | 未持股 | 2024-05-06 |
| Sanjeev Redkar | 男 | President and Director | 55 | 未披露 | 722.08 | 2024-05-06 |
| 余健鸿 | -- | Chief Medical Officer | 61 | 未披露 | 174.92 | 2024-05-06 |
董事简历
中英对照 | 中文 | 英文- 余国良
-
余国良是美国公民。余国良是Apollomics Inc.董事会（“董事会”）主席和首席执行官。
Guo Liang Yu,serves as Apollomics Inc. Chairman and Chief Executive Officer. Since January 2016, Dr. Guo-Liang Yu has served as the Chairman and Chief Executive Officer of Apollomics, which he co-founded. From 2013 to 2018, Dr. Guo-Liang Yu served as Executive Chairman at Crown Bioscience Inc. Dr. Guo-Liang Yu has co-founded several startup companies in biotech and healthcare, including Epitomics Inc. and Immune-Onc Therapeutics, Inc. in Palo Alto, California. Dr. Guo-Liang Yu is the founding president of the Chinese Biopharmaceutical Association USA and Chairman of the Bayhelix Group. Dr. Yu earned a B.S. in Biochemistry from Fudan University, a Ph.D. in Molecular Biology from University of California, Berkeley and was a Post- Doctoral Fellow at Harvard Medical School. - 余国良是美国公民。余国良是Apollomics Inc.董事会（“董事会”）主席和首席执行官。
- Guo Liang Yu,serves as Apollomics Inc. Chairman and Chief Executive Officer. Since January 2016, Dr. Guo-Liang Yu has served as the Chairman and Chief Executive Officer of Apollomics, which he co-founded. From 2013 to 2018, Dr. Guo-Liang Yu served as Executive Chairman at Crown Bioscience Inc. Dr. Guo-Liang Yu has co-founded several startup companies in biotech and healthcare, including Epitomics Inc. and Immune-Onc Therapeutics, Inc. in Palo Alto, California. Dr. Guo-Liang Yu is the founding president of the Chinese Biopharmaceutical Association USA and Chairman of the Bayhelix Group. Dr. Yu earned a B.S. in Biochemistry from Fudan University, a Ph.D. in Molecular Biology from University of California, Berkeley and was a Post- Doctoral Fellow at Harvard Medical School.
- Wendy Hayes
-
Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
Wendy Hayes,has served as Burning Rock Biotech Limited independent director since June 2020. Ms. Hayes has served as an independent director of Tuanche Limited (NASDAQ: TC) since November 2018, iHuman Inc. (NYSE: IH) since October 2020, SciClone Pharmaceuticals (Holdings) Limited (HKEX: 6600) since March 2021, Apollomics Inc. (NASDAQ: APLM) since March 2023 and SharkNinja, Inc. (NYSE: SN) since July 2023. Between May 2013 and September 2018, Ms. Hayes served as the inspections leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes received her bachelor's degree in international finance from University of International Business and Economics in 1991, and her executive MBA from Cheung Kong Graduate School of Business in 2012. Ms. Hayes is a certified public accountant in the United States (California) and China. - Wendy Hayes ，自2020年6月起担任Burning Rock Biotech Limited独立董事。她曾担任Tuanche Limited （NASDAQ： TC）的独立董事（2018年11月以来）、iHuman Inc. （NYSE： IH）、Gracell Biotechnologies Inc. （NASDAQ： GRCL）（2021年1月以来）、SciClone Pharmaceuticals （Holdings） Limited （HKEX： 6600）（2021年3月以来）。2013年5月至2018年9月，她曾担任the Public Company Accounting Oversight Board在美国的检查主管。在此之前，她曾担任Deloitte （中国）的审计合伙人。她于1991年获得对外经济贸易大学国际金融学士学位，并于2012年获得张Kong Graduate School of Business的emba学位。她目前是哈佛大学ALI的高级研究员。她是美国（加州）和中国的注册会计师。
- Wendy Hayes,has served as Burning Rock Biotech Limited independent director since June 2020. Ms. Hayes has served as an independent director of Tuanche Limited (NASDAQ: TC) since November 2018, iHuman Inc. (NYSE: IH) since October 2020, SciClone Pharmaceuticals (Holdings) Limited (HKEX: 6600) since March 2021, Apollomics Inc. (NASDAQ: APLM) since March 2023 and SharkNinja, Inc. (NYSE: SN) since July 2023. Between May 2013 and September 2018, Ms. Hayes served as the inspections leader at the Public Company Accounting Oversight Board in the United States. Prior to that, Ms. Hayes was an audit partner at Deloitte (China). Ms. Hayes received her bachelor's degree in international finance from University of International Business and Economics in 1991, and her executive MBA from Cheung Kong Graduate School of Business in 2012. Ms. Hayes is a certified public accountant in the United States (California) and China.
- Chen, Hong Jung
-
Chen, Hong Jung担任Apollomics Inc.董事会成员。陈博士自2018年5月起担任Maxpro Ventures LTD的董事总经理，Maxpro Ventures LTD是一家专注于突破性生物医学技术公司的投资公司，曾担任Maxpro的董事会主席和首席执行官。此前，2014年10月至2017年1月，陈博士在台湾SyneuRX International Corp.担任副总裁兼代理首席运营官，负责监督公司的日常运营，并亲自与VC代表和私人投资者互动。陈博士在制定和实施小分子、生物制剂和细胞治疗的基础研究和临床前开发战略方面拥有20多年的经验，在推进候选药物从发现到提名IND和开发方面也很有经验。陈博士在罗格斯大学、新泽西州立大学和新泽西医学与牙科大学获得微生物学和分子遗传学博士学位。他在加州理工学院完成了神经科学的博士后培训。
Chen, Hong Jung,serves as a member of Apollomics Inc. board of directors. Dr. Chen has been Managing Director of Maxpro Ventures LTD since May 2018, which is an investment firm focused on breakthrough biomedical technology companies, and served as Chairman of the Board of Directors and Chief Executive Officer of Maxpro. Dr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine, and has served as director of Uneuron Biomedical Co. Ltd. since March 2023, and has been a supervisor of ReVasgen Inc. since October 2014. Previously, from October 2014 to January 2017, Dr. Chen worked as Vice President and Acting Chief Operating Officer for SyneuRx International Corp. in Taiwan, where he was responsible for supervising the company's daily operation and personally interacting with VC representatives and private investors. Dr. Chen has more than 20 years of experience in formulating and implementing basic research and preclinical development strategies for small molecules, biologics and cell therapy and is also experienced in advancing drug candidates from discovery to nomination for IND and development. Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He completed his postdoctoral training in neuroscience at California Institute of Technology. - Chen, Hong Jung担任Apollomics Inc.董事会成员。陈博士自2018年5月起担任Maxpro Ventures LTD的董事总经理，Maxpro Ventures LTD是一家专注于突破性生物医学技术公司的投资公司，曾担任Maxpro的董事会主席和首席执行官。此前，2014年10月至2017年1月，陈博士在台湾SyneuRX International Corp.担任副总裁兼代理首席运营官，负责监督公司的日常运营，并亲自与VC代表和私人投资者互动。陈博士在制定和实施小分子、生物制剂和细胞治疗的基础研究和临床前开发战略方面拥有20多年的经验，在推进候选药物从发现到提名IND和开发方面也很有经验。陈博士在罗格斯大学、新泽西州立大学和新泽西医学与牙科大学获得微生物学和分子遗传学博士学位。他在加州理工学院完成了神经科学的博士后培训。
- Chen, Hong Jung,serves as a member of Apollomics Inc. board of directors. Dr. Chen has been Managing Director of Maxpro Ventures LTD since May 2018, which is an investment firm focused on breakthrough biomedical technology companies, and served as Chairman of the Board of Directors and Chief Executive Officer of Maxpro. Dr. Chen is also an ad hoc reviewer of Stem Cells Translational Medicine, and has served as director of Uneuron Biomedical Co. Ltd. since March 2023, and has been a supervisor of ReVasgen Inc. since October 2014. Previously, from October 2014 to January 2017, Dr. Chen worked as Vice President and Acting Chief Operating Officer for SyneuRx International Corp. in Taiwan, where he was responsible for supervising the company's daily operation and personally interacting with VC representatives and private investors. Dr. Chen has more than 20 years of experience in formulating and implementing basic research and preclinical development strategies for small molecules, biologics and cell therapy and is also experienced in advancing drug candidates from discovery to nomination for IND and development. Dr. Chen received his Ph.D. in Microbiology and Molecular Genetics from Rutgers, The State University of New Jersey and The University of Medicine and Dentistry of New Jersey. He completed his postdoctoral training in neuroscience at California Institute of Technology.
- Sanjeev Redkar
-
Sanjeev Redkar，担任Apollomics Inc.总裁兼首席财务官。自2016年1月起，Redkar博士担任Apollomics的总裁，该公司是他与他人共同创立的。2011年9月至2016年1月，Redkar博士在Astex Pharmaceuticals, Inc.（纳斯达克：ASTX）担任过多个职务，包括负责药物开发和市场营销的副总裁、药物开发和市场营销的高级副总裁以及产品开发的高级副总裁。从1998年6月到2011年9月，Redkar博士在SuperGen，Inc.担任过多个职务，包括工艺开发高级经理、药物开发高级总监以及负责制造和临床前开发的副总裁。Redkar博士自2018年起担任博尔德科罗拉多大学化学与生物工程系外部顾问委员会成员。Redkar博士在印度理工学院获得化学工程学士学位，在科罗拉多大学博尔德分校获得化学工程学硕士学位，在科罗拉多大学博尔德分校获得化学工程学博士学位，并在加州圣玛丽学院获得MBA学位。
Sanjeev Redkar,serves as Apollomics Inc. President and Director. Since January 2016, Dr. Redkar has served as the President of Apollomics, which he co-founded. From September 2011 to January 2016, Dr. Redkar held various roles at Astex Pharmaceuticals, Inc. (Nasdaq: ASTX), including vice president in charge of pharmaceutical development and marketing, senior vice president of pharmaceutical development and marketing and senior vice president of product development. From June 1998 to September 2011, Dr. Redkar held various roles at SuperGen, Inc., including as senior manager of process development, senior director of pharmaceutical development and vice president in charge of manufacturing and preclinical development. Dr. Redkar has served as an External Advisory Board Member at the University of the Pacific, T. J. Longs School of Pharmacy since 2007. Dr. Redkar earned a B.S. in Chemical Engineering from the Indian Institute of Technology, a M.S. in Chemical Engineering from the University of Colorado, Boulder, a Ph.D. in Chemical Engineering from the University of Colorado, Boulder and an MBA from St. Mary's College of California. - Sanjeev Redkar，担任Apollomics Inc.总裁兼首席财务官。自2016年1月起，Redkar博士担任Apollomics的总裁，该公司是他与他人共同创立的。2011年9月至2016年1月，Redkar博士在Astex Pharmaceuticals, Inc.（纳斯达克：ASTX）担任过多个职务，包括负责药物开发和市场营销的副总裁、药物开发和市场营销的高级副总裁以及产品开发的高级副总裁。从1998年6月到2011年9月，Redkar博士在SuperGen，Inc.担任过多个职务，包括工艺开发高级经理、药物开发高级总监以及负责制造和临床前开发的副总裁。Redkar博士自2018年起担任博尔德科罗拉多大学化学与生物工程系外部顾问委员会成员。Redkar博士在印度理工学院获得化学工程学士学位，在科罗拉多大学博尔德分校获得化学工程学硕士学位，在科罗拉多大学博尔德分校获得化学工程学博士学位，并在加州圣玛丽学院获得MBA学位。
- Sanjeev Redkar,serves as Apollomics Inc. President and Director. Since January 2016, Dr. Redkar has served as the President of Apollomics, which he co-founded. From September 2011 to January 2016, Dr. Redkar held various roles at Astex Pharmaceuticals, Inc. (Nasdaq: ASTX), including vice president in charge of pharmaceutical development and marketing, senior vice president of pharmaceutical development and marketing and senior vice president of product development. From June 1998 to September 2011, Dr. Redkar held various roles at SuperGen, Inc., including as senior manager of process development, senior director of pharmaceutical development and vice president in charge of manufacturing and preclinical development. Dr. Redkar has served as an External Advisory Board Member at the University of the Pacific, T. J. Longs School of Pharmacy since 2007. Dr. Redkar earned a B.S. in Chemical Engineering from the Indian Institute of Technology, a M.S. in Chemical Engineering from the University of Colorado, Boulder, a Ph.D. in Chemical Engineering from the University of Colorado, Boulder and an MBA from St. Mary's College of California.
- Kenneth C. Carter
-
Kenneth C. Carter，担任Apollomics Inc.董事会成员。自2020年以来，Carter博士一直担任InnoForce，Inc.的企业发展全球主管和美国业务总裁。Carter博士曾作为联合创始人、顾问、首席执行官和/或董事会成员参与创办和指导多家生物技术公司，其中包括他与他人共同创立并于2011年至2017年担任董事长兼首席执行官、随后担任董事会高级顾问至2019年的NexImmune（纳斯达克：NEXI）以及Seneca Biopharma（纳斯达克：SNCA），并于2019年至2020年担任执行董事长。从1999年到2009年，Carter博士是Avalon Pharmaceuticals（纳斯达克：AVRX，现为艾伯维的一部分）的联合创始人兼首席执行官。Carter博士在阿比林基督教大学获得生物学和化学学士学位，并在得克萨斯大学医学分院获得人类遗传学和细胞生物学博士学位。Carter博士在马萨诸塞大学医学院完成了细胞和分子生物学的博士后培训。
Kenneth C. Carter,serves as a member of Apollomics Inc. board of directors. Since 2020, Dr. Carter has served as the Global Head of Corporate Development and President of US Operations at Innoforce, Inc. Dr. Carter has been involved in starting and guiding several biotechnology companies as a co-founder, advisor, CEO, and/or member of the board of directors, including NexImmune (Nasdaq: NEXI), which he co-founded and served from 2011 to 2017 as Chairman and CEO, later serving as a senior advisor to the board of directors until 2019, and Seneca Biopharma (Nasdaq: SNCA), where he served as Executive Chairman from 2019 to 2020. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharmaceuticals (Nasdaq: AVRX, now part of AbbVie). Dr. Carter received a B.S. in Biology and Chemistry from Abilene Christian University and received his Ph.D. in Human Genetics and Cell Biology from the University of Texas Medical Branch. Dr. Carter completed his postdoctoral training in Cell and Molecular Biology at the University of Massachusetts Medical School. - Kenneth C. Carter，担任Apollomics Inc.董事会成员。自2020年以来，Carter博士一直担任InnoForce，Inc.的企业发展全球主管和美国业务总裁。Carter博士曾作为联合创始人、顾问、首席执行官和/或董事会成员参与创办和指导多家生物技术公司，其中包括他与他人共同创立并于2011年至2017年担任董事长兼首席执行官、随后担任董事会高级顾问至2019年的NexImmune（纳斯达克：NEXI）以及Seneca Biopharma（纳斯达克：SNCA），并于2019年至2020年担任执行董事长。从1999年到2009年，Carter博士是Avalon Pharmaceuticals（纳斯达克：AVRX，现为艾伯维的一部分）的联合创始人兼首席执行官。Carter博士在阿比林基督教大学获得生物学和化学学士学位，并在得克萨斯大学医学分院获得人类遗传学和细胞生物学博士学位。Carter博士在马萨诸塞大学医学院完成了细胞和分子生物学的博士后培训。
- Kenneth C. Carter,serves as a member of Apollomics Inc. board of directors. Since 2020, Dr. Carter has served as the Global Head of Corporate Development and President of US Operations at Innoforce, Inc. Dr. Carter has been involved in starting and guiding several biotechnology companies as a co-founder, advisor, CEO, and/or member of the board of directors, including NexImmune (Nasdaq: NEXI), which he co-founded and served from 2011 to 2017 as Chairman and CEO, later serving as a senior advisor to the board of directors until 2019, and Seneca Biopharma (Nasdaq: SNCA), where he served as Executive Chairman from 2019 to 2020. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharmaceuticals (Nasdaq: AVRX, now part of AbbVie). Dr. Carter received a B.S. in Biology and Chemistry from Abilene Christian University and received his Ph.D. in Human Genetics and Cell Biology from the University of Texas Medical Branch. Dr. Carter completed his postdoctoral training in Cell and Molecular Biology at the University of Massachusetts Medical School.
- Glenn S. Vraniak
-
Glenn S. Vraniak，担任Apollomics Inc.董事会成员。自2022年5月起，Vraniak先生担任Inversago Pharma Inc.的首席财务官。2021年11月至2022年4月，Vraniak先生担任法雷奥自主汽车技术部门的首席财务官，法雷奥是一家总部位于巴黎的上市公司，专注于汽车领域。从2019年10月至2021年10月，Vraniak先生在Evaxion Biotech A/S（EVAX）担任首席财务官，在那里他领导公司完成了首次公开发行股票。2016年8月至2019年4月，Vraniak先生担任electroCore，Inc.的首席财务官，在那里他带领公司完成了首次公开发行股票（ECOR）。Vraniak先生获得了罗格斯大学管理发展中心的电气工程技术学位和管理MBA学位。
Glenn S. Vraniak,serves as a member of Apollomics Inc. board of directors. Since May 2022, Mr. Vraniak has served as the Chief Financial Officer of Inversago Pharma Inc. From November 2021 to April 2022, Mr. Vraniak served as Chief Financial Officer of the autonomous automotive technology division of Valeo, a Paris-based public company focused on the automotive sector. From October 2019 to October 2021, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S (Nasdaq: EVAX), where he led the company through an initial public offering. From August 2016 to April 2019, Mr. Vraniak served as Chief Financial Officer of electroCore, Inc. (Nasdaq: ECOR), where he led the company through an initial public offering. Mr. Vraniak earned an electrical engineering technology degree and a managerial MBA from the Rutgers University Center for Management Development. - Glenn S. Vraniak，担任Apollomics Inc.董事会成员。自2022年5月起，Vraniak先生担任Inversago Pharma Inc.的首席财务官。2021年11月至2022年4月，Vraniak先生担任法雷奥自主汽车技术部门的首席财务官，法雷奥是一家总部位于巴黎的上市公司，专注于汽车领域。从2019年10月至2021年10月，Vraniak先生在Evaxion Biotech A/S（EVAX）担任首席财务官，在那里他领导公司完成了首次公开发行股票。2016年8月至2019年4月，Vraniak先生担任electroCore，Inc.的首席财务官，在那里他带领公司完成了首次公开发行股票（ECOR）。Vraniak先生获得了罗格斯大学管理发展中心的电气工程技术学位和管理MBA学位。
- Glenn S. Vraniak,serves as a member of Apollomics Inc. board of directors. Since May 2022, Mr. Vraniak has served as the Chief Financial Officer of Inversago Pharma Inc. From November 2021 to April 2022, Mr. Vraniak served as Chief Financial Officer of the autonomous automotive technology division of Valeo, a Paris-based public company focused on the automotive sector. From October 2019 to October 2021, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S (Nasdaq: EVAX), where he led the company through an initial public offering. From August 2016 to April 2019, Mr. Vraniak served as Chief Financial Officer of electroCore, Inc. (Nasdaq: ECOR), where he led the company through an initial public offering. Mr. Vraniak earned an electrical engineering technology degree and a managerial MBA from the Rutgers University Center for Management Development.
- Bob Lin
-
Bob Lin是一名医生和研究员，曾进行多国临床试验，并在基因组学，蛋白质组学和生物技术交易方面经验丰富。Lin博士曾任台湾某三级医疗中心内科副主任，并在美国劳伦斯伯克利实验室进行博士后研究。
Bob Lin,is a physician and researcher who has conducted multinational clinical trials and is experienced in genomics, proteomics and biotech transactions. Dr. Lin has served as the vice director of the Internal Medicine Department at a tertiary medical center in Taiwan and conducted post-doctoral research at Lawrence Berkeley Laboratory in the United States. - Bob Lin是一名医生和研究员，曾进行多国临床试验，并在基因组学，蛋白质组学和生物技术交易方面经验丰富。Lin博士曾任台湾某三级医疗中心内科副主任，并在美国劳伦斯伯克利实验室进行博士后研究。
- Bob Lin,is a physician and researcher who has conducted multinational clinical trials and is experienced in genomics, proteomics and biotech transactions. Dr. Lin has served as the vice director of the Internal Medicine Department at a tertiary medical center in Taiwan and conducted post-doctoral research at Lawrence Berkeley Laboratory in the United States.
高管简历
中英对照 | 中文 | 英文- 余国良
余国良是美国公民。余国良是Apollomics Inc.董事会（“董事会”）主席和首席执行官。
Guo Liang Yu,serves as Apollomics Inc. Chairman and Chief Executive Officer. Since January 2016, Dr. Guo-Liang Yu has served as the Chairman and Chief Executive Officer of Apollomics, which he co-founded. From 2013 to 2018, Dr. Guo-Liang Yu served as Executive Chairman at Crown Bioscience Inc. Dr. Guo-Liang Yu has co-founded several startup companies in biotech and healthcare, including Epitomics Inc. and Immune-Onc Therapeutics, Inc. in Palo Alto, California. Dr. Guo-Liang Yu is the founding president of the Chinese Biopharmaceutical Association USA and Chairman of the Bayhelix Group. Dr. Yu earned a B.S. in Biochemistry from Fudan University, a Ph.D. in Molecular Biology from University of California, Berkeley and was a Post- Doctoral Fellow at Harvard Medical School.- 余国良是美国公民。余国良是Apollomics Inc.董事会（“董事会”）主席和首席执行官。
- Guo Liang Yu,serves as Apollomics Inc. Chairman and Chief Executive Officer. Since January 2016, Dr. Guo-Liang Yu has served as the Chairman and Chief Executive Officer of Apollomics, which he co-founded. From 2013 to 2018, Dr. Guo-Liang Yu served as Executive Chairman at Crown Bioscience Inc. Dr. Guo-Liang Yu has co-founded several startup companies in biotech and healthcare, including Epitomics Inc. and Immune-Onc Therapeutics, Inc. in Palo Alto, California. Dr. Guo-Liang Yu is the founding president of the Chinese Biopharmaceutical Association USA and Chairman of the Bayhelix Group. Dr. Yu earned a B.S. in Biochemistry from Fudan University, a Ph.D. in Molecular Biology from University of California, Berkeley and was a Post- Doctoral Fellow at Harvard Medical School.
- 马修 普朗克特
马修 普朗克特，最近担任Aeovian Pharmaceuticals的首席财务官。在加入Aeovian之前，他在Imago Biosciences（已被默沙东收购）担任首席财务官，在那里他领导了该公司1.55亿美元的纳斯达克首次公开募股（IPO）。他此前担任Nkarta Therapeutics的首席财务官，在该公司牵头进行了2.9亿美元的纳斯达克 IPO。他曾在CTI BioPharma（已被SOBI收购）担任过首席商务官等职务，这是一家商业阶段的血液肿瘤生物制药公司，在那里他领导了各种融资和企业发展交易。职业生涯早期，Plunkett博士曾在CIBC World Markets及其美国继任者Oppenheimer & Co.担任过多个职位，包括董事总经理、西海岸生物技术负责人。Plunkett博士在哈维·穆德学院获得化学学士学位，在加州大学伯克利分校获得有机化学博士学位。
Matthew Plunkett,serves as Apollomics Inc. Chief Financial Officer and Principal Financial Officer. Since March 2024, Dr. Plunkett has served as the Chief Financial Officer of Apollomics. Prior to joining Apollomics, he was Chief Financial Officer at Aeovian Pharmaceuticals from March 2022 to February 2024. From January 2021 to September 2021, he served as Chief Financial Officer at Imago Biosciences (Nasdaq: IMGO). Dr. Plunkett served as Chief Financial Officer of Nkarta Therapeutics (Nasdaq: NKTX), from September 2019 until October 2020 and as Senior Vice President and Chief Financial Officer from November 2018 to September 2019. Previously, Dr. Plunkett served as Chief Financial and Business Officer of Medeor Therapeutics from September 2017 and November 2018. Prior to that, he served as Chief Business Officer of CTI BioPharma (Nasdaq: CTIC), a publicly traded biopharmaceutical company, from December 2015 to August 2017 and as Executive Vice President Corporate Development from September 2012 until December 2015. From November 2011 to August 2012, he served as the Chief Financial Officer of the California Institute for Regenerative Medicine. Dr. Plunkett served as the Vice President and Chief Financial Officer of iPierian, Inc. from July 2009 to April 2011. From December 2000 to July 2009, Dr. Plunkett held positions at Oppenheimer & Co. Inc. and its U.S. predecessor, CIBC World Markets Corp., including as Managing Director and Head of West Coast Biotechnology. Dr. Plunkett holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Chemistry from University of California, Berkeley.- 马修 普朗克特，最近担任Aeovian Pharmaceuticals的首席财务官。在加入Aeovian之前，他在Imago Biosciences（已被默沙东收购）担任首席财务官，在那里他领导了该公司1.55亿美元的纳斯达克首次公开募股（IPO）。他此前担任Nkarta Therapeutics的首席财务官，在该公司牵头进行了2.9亿美元的纳斯达克 IPO。他曾在CTI BioPharma（已被SOBI收购）担任过首席商务官等职务，这是一家商业阶段的血液肿瘤生物制药公司，在那里他领导了各种融资和企业发展交易。职业生涯早期，Plunkett博士曾在CIBC World Markets及其美国继任者Oppenheimer & Co.担任过多个职位，包括董事总经理、西海岸生物技术负责人。Plunkett博士在哈维·穆德学院获得化学学士学位，在加州大学伯克利分校获得有机化学博士学位。
- Matthew Plunkett,serves as Apollomics Inc. Chief Financial Officer and Principal Financial Officer. Since March 2024, Dr. Plunkett has served as the Chief Financial Officer of Apollomics. Prior to joining Apollomics, he was Chief Financial Officer at Aeovian Pharmaceuticals from March 2022 to February 2024. From January 2021 to September 2021, he served as Chief Financial Officer at Imago Biosciences (Nasdaq: IMGO). Dr. Plunkett served as Chief Financial Officer of Nkarta Therapeutics (Nasdaq: NKTX), from September 2019 until October 2020 and as Senior Vice President and Chief Financial Officer from November 2018 to September 2019. Previously, Dr. Plunkett served as Chief Financial and Business Officer of Medeor Therapeutics from September 2017 and November 2018. Prior to that, he served as Chief Business Officer of CTI BioPharma (Nasdaq: CTIC), a publicly traded biopharmaceutical company, from December 2015 to August 2017 and as Executive Vice President Corporate Development from September 2012 until December 2015. From November 2011 to August 2012, he served as the Chief Financial Officer of the California Institute for Regenerative Medicine. Dr. Plunkett served as the Vice President and Chief Financial Officer of iPierian, Inc. from July 2009 to April 2011. From December 2000 to July 2009, Dr. Plunkett held positions at Oppenheimer & Co. Inc. and its U.S. predecessor, CIBC World Markets Corp., including as Managing Director and Head of West Coast Biotechnology. Dr. Plunkett holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Chemistry from University of California, Berkeley.
- Sanjeev Redkar
Sanjeev Redkar，担任Apollomics Inc.总裁兼首席财务官。自2016年1月起，Redkar博士担任Apollomics的总裁，该公司是他与他人共同创立的。2011年9月至2016年1月，Redkar博士在Astex Pharmaceuticals, Inc.（纳斯达克：ASTX）担任过多个职务，包括负责药物开发和市场营销的副总裁、药物开发和市场营销的高级副总裁以及产品开发的高级副总裁。从1998年6月到2011年9月，Redkar博士在SuperGen，Inc.担任过多个职务，包括工艺开发高级经理、药物开发高级总监以及负责制造和临床前开发的副总裁。Redkar博士自2018年起担任博尔德科罗拉多大学化学与生物工程系外部顾问委员会成员。Redkar博士在印度理工学院获得化学工程学士学位，在科罗拉多大学博尔德分校获得化学工程学硕士学位，在科罗拉多大学博尔德分校获得化学工程学博士学位，并在加州圣玛丽学院获得MBA学位。
Sanjeev Redkar,serves as Apollomics Inc. President and Director. Since January 2016, Dr. Redkar has served as the President of Apollomics, which he co-founded. From September 2011 to January 2016, Dr. Redkar held various roles at Astex Pharmaceuticals, Inc. (Nasdaq: ASTX), including vice president in charge of pharmaceutical development and marketing, senior vice president of pharmaceutical development and marketing and senior vice president of product development. From June 1998 to September 2011, Dr. Redkar held various roles at SuperGen, Inc., including as senior manager of process development, senior director of pharmaceutical development and vice president in charge of manufacturing and preclinical development. Dr. Redkar has served as an External Advisory Board Member at the University of the Pacific, T. J. Longs School of Pharmacy since 2007. Dr. Redkar earned a B.S. in Chemical Engineering from the Indian Institute of Technology, a M.S. in Chemical Engineering from the University of Colorado, Boulder, a Ph.D. in Chemical Engineering from the University of Colorado, Boulder and an MBA from St. Mary's College of California.- Sanjeev Redkar，担任Apollomics Inc.总裁兼首席财务官。自2016年1月起，Redkar博士担任Apollomics的总裁，该公司是他与他人共同创立的。2011年9月至2016年1月，Redkar博士在Astex Pharmaceuticals, Inc.（纳斯达克：ASTX）担任过多个职务，包括负责药物开发和市场营销的副总裁、药物开发和市场营销的高级副总裁以及产品开发的高级副总裁。从1998年6月到2011年9月，Redkar博士在SuperGen，Inc.担任过多个职务，包括工艺开发高级经理、药物开发高级总监以及负责制造和临床前开发的副总裁。Redkar博士自2018年起担任博尔德科罗拉多大学化学与生物工程系外部顾问委员会成员。Redkar博士在印度理工学院获得化学工程学士学位，在科罗拉多大学博尔德分校获得化学工程学硕士学位，在科罗拉多大学博尔德分校获得化学工程学博士学位，并在加州圣玛丽学院获得MBA学位。
- Sanjeev Redkar,serves as Apollomics Inc. President and Director. Since January 2016, Dr. Redkar has served as the President of Apollomics, which he co-founded. From September 2011 to January 2016, Dr. Redkar held various roles at Astex Pharmaceuticals, Inc. (Nasdaq: ASTX), including vice president in charge of pharmaceutical development and marketing, senior vice president of pharmaceutical development and marketing and senior vice president of product development. From June 1998 to September 2011, Dr. Redkar held various roles at SuperGen, Inc., including as senior manager of process development, senior director of pharmaceutical development and vice president in charge of manufacturing and preclinical development. Dr. Redkar has served as an External Advisory Board Member at the University of the Pacific, T. J. Longs School of Pharmacy since 2007. Dr. Redkar earned a B.S. in Chemical Engineering from the Indian Institute of Technology, a M.S. in Chemical Engineering from the University of Colorado, Boulder, a Ph.D. in Chemical Engineering from the University of Colorado, Boulder and an MBA from St. Mary's College of California.
- 余健鸿
余健鸿，担任Apollomics Inc.首席医疗官。余博士自2021年3月起担任Apollomics首席医疗官。从2008年到2021年，余博士曾在珐博进公司（纳斯达克：FGEN）担任多个职务，包括从2016年4月到2020年12月担任首席医疗官和高级副总裁。2006年至2008年，余博士担任Anesiva（纳斯达克：ANSV）临床开发副总裁，并于2004年至2006年担任ALZA Corporation临床开发总监。自2021年1月起，余博士担任STAAR Surgical（纳斯达克：STAA）的董事会成员。余博士获得了加州大学戴维斯医学院的医学博士学位。
Kin Hung Peony Yu,serves as Apollomics Inc. Chief Medical Officer. Dr. Yu has served as the Chief Medical Officer of Apollomics since March 2021. From 2008 to 2021, Dr. Yu served in various roles at FibroGen, Inc. (Nasdaq: FGEN), including as Chief Medical Officer and Senior Vice President from April 2016 to December 2020. From 2006 to 2008, Dr. Yu served as Vice President of Clinical Development for Anesiva (Nasdaq: ANSV) and served as the Director, Clinical Development of ALZA Corporation from 2004 to 2006. Since January 2021, Dr. Yu has served on the board of directors of STAAR Surgical (Nasdaq: STAA). Dr. Yu earned an M.D. from the University of California, Davis School of Medicine.- 余健鸿，担任Apollomics Inc.首席医疗官。余博士自2021年3月起担任Apollomics首席医疗官。从2008年到2021年，余博士曾在珐博进公司（纳斯达克：FGEN）担任多个职务，包括从2016年4月到2020年12月担任首席医疗官和高级副总裁。2006年至2008年，余博士担任Anesiva（纳斯达克：ANSV）临床开发副总裁，并于2004年至2006年担任ALZA Corporation临床开发总监。自2021年1月起，余博士担任STAAR Surgical（纳斯达克：STAA）的董事会成员。余博士获得了加州大学戴维斯医学院的医学博士学位。
- Kin Hung Peony Yu,serves as Apollomics Inc. Chief Medical Officer. Dr. Yu has served as the Chief Medical Officer of Apollomics since March 2021. From 2008 to 2021, Dr. Yu served in various roles at FibroGen, Inc. (Nasdaq: FGEN), including as Chief Medical Officer and Senior Vice President from April 2016 to December 2020. From 2006 to 2008, Dr. Yu served as Vice President of Clinical Development for Anesiva (Nasdaq: ANSV) and served as the Director, Clinical Development of ALZA Corporation from 2004 to 2006. Since January 2021, Dr. Yu has served on the board of directors of STAAR Surgical (Nasdaq: STAA). Dr. Yu earned an M.D. from the University of California, Davis School of Medicine.